Monthly Archives: May 2017

“Increasing age is the biggest risk for Alzheimer’s disease, and therefore identification of elderly individuals in the pre-symptomatic stages when disease-modifying therapies might be most beneficial is of interest. A logical approach is to use biomarkers of core Alzheimer’s disease … Continue reading

Posted in Uncategorized | Comments Off on Imaging the ageing brain: identifying early disease or opening Pandora’s box?

The balance between pro-aging and counteracting homeostatic mechanisms largely determines the progression of aging. The endocannabinoid system is thought to be part of the latter system because it modulates the physiological processes underlying aging. Its activity declines during aging and … Continue reading

Posted in Uncategorized | Comments Off on Cannabinoids and cognition

“Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade … Continue reading

Posted in Uncategorized | Comments Off on Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine

“In an elegant feat of synthetic biology, Shao and colleagues were able to remotely control release of glucose-lowering hormones by engineered cells implanted into diabetic mice. These designer cells were transfected with optogenetic circuits, which enabled them to produce the … Continue reading

Posted in Uncategorized | Comments Off on Smartphone controlled optogenetically engineered cells